Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
9.23
-0.08 (-0.86%)
Mar 28, 2025, 4:00 PM EDT - Market closed
Theravance Biopharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 64.38 | 57.42 | 51.35 | 55.31 | 71.86 | Upgrade
|
| Revenue Growth (YoY) | 12.12% | 11.84% | -7.17% | -23.03% | -2.12% | Upgrade
|
| Cost of Revenue | 37.64 | 40.62 | 63.39 | 193.66 | 260.95 | Upgrade
|
| Gross Profit | 26.74 | 16.8 | -12.05 | -138.35 | -189.1 | Upgrade
|
| Selling, General & Admin | 69.17 | 70.1 | 67.07 | 99.3 | 108.53 | Upgrade
|
| Operating Expenses | 69.17 | 70.45 | 67.07 | 99.3 | 108.53 | Upgrade
|
| Operating Income | -42.44 | -53.65 | -79.12 | -237.64 | -297.63 | Upgrade
|
| Interest Expense | -2.55 | -2.35 | -6.37 | -8.55 | -8.55 | Upgrade
|
| Interest & Investment Income | 4.98 | 9.02 | 6.74 | 2.01 | 4.74 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.1 | 0.1 | -0.9 | -0.9 | -0.3 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | - | -1.61 | Upgrade
|
| EBT Excluding Unusual Items | -40.1 | -46.88 | -79.65 | -245.08 | -303.34 | Upgrade
|
| Merger & Restructuring Charges | - | -2.39 | -12.84 | -20.14 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 2.71 | - | - | Upgrade
|
| Asset Writedown | -4.51 | - | - | - | - | Upgrade
|
| Other Unusual Items | - | - | -3.03 | - | - | Upgrade
|
| Pretax Income | -44.61 | -49.27 | -92.82 | -265.22 | -303.34 | Upgrade
|
| Income Tax Expense | 11.8 | 5.92 | 0.01 | -0.15 | -8.52 | Upgrade
|
| Earnings From Continuing Operations | -56.42 | -55.19 | -92.82 | -265.07 | -294.82 | Upgrade
|
| Earnings From Discontinued Operations | - | - | 964.96 | 65.65 | 16.81 | Upgrade
|
| Net Income | -56.42 | -55.19 | 872.13 | -199.43 | -278.02 | Upgrade
|
| Net Income to Common | -56.42 | -55.19 | 872.13 | -199.43 | -278.02 | Upgrade
|
| Shares Outstanding (Basic) | 49 | 55 | 74 | 69 | 62 | Upgrade
|
| Shares Outstanding (Diluted) | 49 | 55 | 74 | 69 | 62 | Upgrade
|
| Shares Change (YoY) | -11.67% | -24.85% | 5.95% | 11.41% | 12.11% | Upgrade
|
| EPS (Basic) | -1.15 | -1.00 | 11.85 | -2.87 | -4.46 | Upgrade
|
| EPS (Diluted) | -1.15 | -1.00 | 11.85 | -2.87 | -4.46 | Upgrade
|
| Free Cash Flow | -11.87 | -29.49 | -187.56 | -211.26 | -257.02 | Upgrade
|
| Free Cash Flow Per Share | -0.24 | -0.53 | -2.55 | -3.04 | -4.12 | Upgrade
|
| Gross Margin | 41.53% | 29.26% | -23.46% | -250.12% | -263.16% | Upgrade
|
| Operating Margin | -65.91% | -93.43% | -154.09% | -429.65% | -414.19% | Upgrade
|
| Profit Margin | -87.63% | -96.11% | 1698.54% | -360.55% | -386.90% | Upgrade
|
| Free Cash Flow Margin | -18.43% | -51.35% | -365.29% | -381.96% | -357.68% | Upgrade
|
| EBITDA | -40.73 | -51.65 | -76.08 | -232.83 | -294 | Upgrade
|
| EBITDA Margin | -63.26% | -89.94% | -148.18% | - | - | Upgrade
|
| D&A For EBITDA | 1.71 | 2 | 3.04 | 4.81 | 3.63 | Upgrade
|
| EBIT | -42.44 | -53.65 | -79.12 | -237.64 | -297.63 | Upgrade
|
| EBIT Margin | -65.91% | -93.43% | -154.09% | - | - | Upgrade
|
| Revenue as Reported | 64.38 | 57.42 | 51.35 | 55.31 | 71.86 | Upgrade
|
| Advertising Expenses | 4.3 | 5.1 | 8 | 9.3 | 6.3 | Upgrade
|
Updated Mar 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.